This functionality is implemented using Javascript. It cannot work without it, etc...

Estamos cargando la información...

Saltar al contenido

Treatment of Hereditary Transthyretin-Mediated Amyloidosis in Adult Patients

Patisiran and inotersen are considered medically necessary when ALL of the following are met:Individual has a confirmatory diagnosis of hATTR by a genetic test AND tissue biopsy showing amyloid deposition

Presence of clinical signs and symptoms of polyneuropathy characterized by ONE of the following:

Baseline polyneuropathy disability (PND) IIIb or lower (see Table 1 in background section)

Baseline FAP Stage one or two (see Table 1 in background section)

Individual does not have ANY of the following

New York Heart Association (NYHA) class III or IV heart failure

Sensorimotor or autonomic neuropathy not related to hATTR amyloidosis (monoclonal gammopathy, autoimmune disease, etc.).

Prior liver transplantation.

The prescriber is a specialist in the area of the patient’s diagnosis (e.g. neurologist) or the prescriber has consulted with a specialist in the area of the patient’s diagnosis

The patient does NOT have any FDA labeled contraindications to the requested agent and is intended to be used consistently with the FDA approved label (see policy guidelines).

Patisiran and inotersen are considered investigational in all other situations.

787-277-6653 787-474-6326